T2 Biosystems Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Craig Jalbert

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	3.8yrs
Board average tenure	3.5yrs

Recent management updates

Recent updates

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

Sep 22

T2 Biosystems' Survival Riddle

Aug 26

CEO

Craig Jalbert (63 yo)

less than a year

Tenure

Mr. Craig R. Jalbert, CIRA, serves as President, Corporate Secretary & Director of Unity Biotechnology, Inc. from June 27, 2025. Mr. Jalbert is CEO, President, Corporate Treasurer, Corporate Secretary & Di...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Craig Jalbert	CEO, President	less than a year	no data	no data
Kelley Morgan	Chief People Officer	11.6yrs	no data	no data
Brett Giffin	Chief Commercial Officer	3.9yrs	no data	0.00027% $ 0.8
Roger Smith	Senior Vice President of Science Research & Development	3.6yrs	no data	no data

3.8yrs

Average Tenure

61.5yo

Average Age

Experienced Management: TTOO's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Craig Jalbert	CEO, President	less than a year	no data	no data
Eric Rosenberg	Member of Clinical Advisory Board	14.4yrs	no data	no data
Louis Rice	Member of Clinical Advisory Board	14.4yrs	no data	no data
Michael Rybak	Member of Scientific Advisory Board	3.5yrs	no data	no data
James Snyder	Member of Scientific Advisory Board	3.5yrs	no data	no data
Ninfa Saunders	Independent Director	5.3yrs	US$50.00k	0.00026% $ 0.8
Thomas Walsh	Member of Scientific Advisory Board	3.5yrs	no data	no data
Peter Pappas	Member of Clinical Advisory Board	14.4yrs	no data	no data
Michael Pfaller	Member of Clinical Advisory Board	8.2yrs	US$1.10m	no data
Sean Zhang	Member of Scientific Advisory Board	3.5yrs	no data	no data
Denise Uettwiller-Geiger	Member of Scientific Advisory Board	3.5yrs	no data	no data
George Pankey	Member of Scientific Advisory Board	3.5yrs	no data	no data

3.5yrs

Average Tenure

73yo

Average Age

Experienced Board: TTOO's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/06 03:24
End of Day Share Price	2025/10/03 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

T2 Biosystems, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Benjamin Haynor	Alliance Global Partners
Karen Koski	BTIG
Kyle Mikson	Canaccord Genuity

T2 Biosystems Management

Management criteria checks 2/4

Key information

Recent management updates

T2 Biosystems, Inc. Announces CFO Changes

T2 Biosystems, Inc. Announces Board and Committee Changes

T2 Biosystems, Inc., Annual General Meeting, Dec 30, 2024

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

Insufficient new directors

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

Recent updates

Nasdaq to Delist Common Stock of T2 Biosystems

T2 Biosystems, Inc. Announces CFO Changes

T2 Biosystems, Inc. Announces Board and Committee Changes

T2 Biosystems, Inc. announced delayed annual 10-K filing

T2 Biosystems, Inc. Approves Reduction-In-Force of Substantially All of Its Employees

T2 Biosystems, Inc.(OTCPK:TTOO) dropped from S&P TMI Index

T2 Biosystems, Inc.(OTCPK:TTOO) dropped from NASDAQ Composite Index

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

T2 Biosystems Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

T2 Biosystems, Inc., Annual General Meeting, Dec 30, 2024

T2 Biosystems Receives Letter from the Nasdaq Regarding Listing Rule 5550(b)(2)

T2 Biosystems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

T2 Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter 2024

T2 Biosystems, Inc. Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

T2 Biosystems, Inc. to Report Q2, 2024 Results on Jul 29, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering in the amount of $14.658742 million.

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. has withdrawn its Follow-on Equity Offering.

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient new directors

T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference

Consensus revenue estimates decrease by 21%, EPS upgraded

T2 Biosystems Provides Nasdaq Compliance Update

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

Full year 2022 earnings: EPS misses analyst expectations

Consensus revenue estimates decrease by 50%, EPS upgraded

T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Consensus EPS estimates fall by 15%

Price target decreased to US$1.85

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M